Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Cardiac Monitoring of Patients on Btki for Chronic Lymphocytic Leukemia

Christine Gruessner, Alessandra Brofferio, Emily Tomasulo, Jeanine Superata, Shellin Jose, Susan Soto, Said Hafizullah Fayaz, Christopher Pleyer, Pia Nierman, Ovsanna Melikyan, Adrian Wiestner, Mark Haigney, Clare Sun

Blood (2024) 144 (Supplement 1): 6787.

https://doi.org/10.1182/blood-2024-205119

Published: 2024

Journal Articles

Activity and Safety of Venetoclax without Anti-CD20 Lead-in Therapy in Treatment Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia

Christopher Pleyer, Emily Tomasulo, Jeanine Superata, Rachel Adams, Xin Tian, Jayson Grey, Pia Nierman, Adrian Wiestner, Clare Sun

Blood (2024) 144 (Supplement 1): 4620.

https://doi.org/10.1182/blood-2024-203506

Published: 2024

Journal Articles

Polyfunctional Effector PD-1 + CD8 + T Cells and M1 Macrophages Promote Immune Checkpoint Blockade Response in Richter Syndrome Mouse Models

Elisa Ten Hacken, Johan Gustafsson, Chiara Tomasoni, Gabriela Brunsting Hoffmann, Kayla Cruz, Wesley S Lu, Shuqiang Li, Nicholas Haradhvala, Connor Johnson, Stephanie Deng, Xia Bu, Donna S. Neuberg, Othman Al-Sawaf, Barbara F. Eichhorst, Clare Sun, Erin M. Parry, Gordon J. Freeman, Gad Getz, Catherine J. Wu

Blood (2024) 144 (Supplement 1): 761.

https://doi.org/10.1182/blood-2024-201006

Published: 2024

Journal Articles

T Cells from CLL Patients on Venetoclax Mount Potent Cytotoxic Responses in Combination with Epcoritamab, a CD20/CD3 Bispecific Antibody

Layla M. Saleh, Maissa Mhibik, Heribert Playà-Albinyana, Clare Sun, Christopher Pleyer, Adrian Wiestner

Blood (2024) 144 (Supplement 1): 3231.

https://doi.org/10.1182/blood-2024-198141

Published: 2024

Journal Articles

T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia

Blood (2024) 144 (5): 510–524.

https://doi.org/10.1182/blood.2023021990

Published: 2024

Includes: Supplemental data

Journal Articles

Transcriptional Changes in Patients with CLL Starting Venetoclax Therapy Identifies Inflammatory and Adaptive Stress Responses

Layla M. Saleh, Maissa Mhibik, Jonathan Chen, Clare Sun, Christopher Pleyer, Adrian Wiestner

Blood (2023) 142 (Supplement 1): 4196.

https://doi.org/10.1182/blood-2023-190376

Published: 2023

Journal Articles

Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study

Andy Itsara, Clare Sun, Emily Bryer, Inhye E Ahn, Susan Soto, Hao-Wei Wang, Constance M. Yuan, Adrian Wiestner

Blood (2023) 142 (Supplement 1): 201.

https://doi.org/10.1182/blood-2023-182397

Published: 2023

Journal Articles

Extended Follow-up and Resistance Mutations in CLL Patients Treated with Acalabrutinib

Clare Sun, Raghuveer Mali, Rachel Kositsky, Xin Tian, Hannah Tomczak, Barrett Nuttall, Rafael White, Simon Rule, Veerendra Munugalavadla, Adrian Wiestner

Blood (2023) 142 (Supplement 1): 1891.

https://doi.org/10.1182/blood-2023-178819

Published: 2023

Journal Articles

A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies

Blood (2023) 142 (Supplement 1): 4463.

https://doi.org/10.1182/blood-2023-179872

Published: 2023

Journal Articles

NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts

Blood (2023) 141 (13): 1584–1596.

https://doi.org/10.1182/blood.2022016934

Published: 2023

Includes: Supplemental data

Journal Articles

NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies

Blood (2022) 140 (Supplement 1): 2329–2332.

https://doi.org/10.1182/blood-2022-164772

Published: 2022

Journal Articles

Comprehensive Cardiac Testing in Asymptomatic Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib

Andy Itsara, Clare Sun, Inhye E. Ahn, Susan Soto, Douglas Rosing, Mark Haigney, Adrian Wiestner

Blood (2022) 140 (Supplement 1): 4169–4170.

https://doi.org/10.1182/blood-2022-159716

Published: 2022

Journal Articles

Booster and Btki Interruption Improve Response to Sars-Cov-2 Vaccine in Patients with CLL

Emily Bryer, Shira Paul, Jonathan Chen, Christopher Pleyer, Adrian Wiestner, Clare Sun

Blood (2022) 140 (Supplement 1): 9896–9897.

https://doi.org/10.1182/blood-2022-162365

Published: 2022

Journal Articles

CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression Free Survival on BTK Inhibitor Therapy

Anfal Alsadhan, Jonathan Chen, Clare Sun, Chingiz Underbayev, Elena Bibikova, Tanja Nicole Hartmann, Maissa Mhibik, Adrian Wiestner

Blood (2022) 140 (Supplement 1): 6004–6005.

https://doi.org/10.1182/blood-2022-163370

Published: 2022

Journal Articles

Ibrutinib-Associated Sudden Death in Patients with CLL

Emily Bryer, Andy Itsara, Inhye E. Ahn, Beth Kozel, Cody Peer, William D. Figg, Adrian Wiestner, Clare Sun

Blood (2022) 140 (Supplement 1): 4133–4134.

https://doi.org/10.1182/blood-2022-160397

Published: 2022

Journal Articles

Co-Stimulatory Signaling Boosts CAR T Cell Efficacy Against CLL

Ziran Zhao, McKensie Collins, Clare Sun, Adrian Wiestner, J. Joseph Melenhorst

Blood (2022) 140 (Supplement 1): 10255–10256.

https://doi.org/10.1182/blood-2022-158614

Published: 2022

Journal Articles

Longitudinal Mutation Profiling in CLL Patients during Acalabrutinib Therapy and at Progression

Clare Sun, Melih Acar, David Jenkins, Barrett Nuttall, Rafael White, Veerendra Munugalavadla, Adrian Wiestner

Blood (2022) 140 (Supplement 1): 9847–9848.

https://doi.org/10.1182/blood-2022-159525

Published: 2022

Journal Articles

BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL

Maissa Mhibik, Erika M. Gaglione, David Eik, Ellen K. Kendall, Amy Blackburn, Keyvan Keyvanfar, Maria Joao Baptista, Inhye E. Ahn, Clare Sun, Junpeng Qi, Christoph Rader, Adrian Wiestner

Blood (2021) 138 (19): 1843–1854.

https://doi.org/10.1182/blood.2020009686

Published: 2021

Includes: Supplemental data

Journal Articles

Humoral and Cellular Immunogenicity of COVID-19 Vaccinations in Patients with CLL

Clare Sun, Erika M Gaglione, Lauren T Vaughn, Rui Mu, Chingiz Underbayev, Jonathan Chen, Christopher Pleyer, Adrian Wiestner

Blood (2021) 138 (Supplement 1): 3724.

https://doi.org/10.1182/blood-2021-148887

Published: 2021

Journal Articles

Effect of Bruton Tyrosine Kinase Inhibitor on Serologic and Cellular Immune Responses to Recombinant Zoster Vaccine

Christopher Pleyer, Kerry J Laing, Mir Ali, Christopher L McClurkan, Susan Soto, Inhye E. Ahn, Pia Nierman, Emeline Maddux, Jennifer Lotter, Jeanine Superata, Xin Tian, Erika M Gaglione, Adrian Wiestner, Jeffrey Cohen, David M Koelle, Clare Sun

Blood (2021) 138 (Supplement 1): 1556.

https://doi.org/10.1182/blood-2021-148539

Published: 2021

NARROW

Cardiac Monitoring of Patients on Btki for Chronic Lymphocytic Leukemia

Activity and Safety of Venetoclax without Anti-CD20 Lead-in Therapy in Treatment Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia

Polyfunctional Effector PD-1 + CD8 + T Cells and M1 Macrophages Promote Immune Checkpoint Blockade Response in Richter Syndrome Mouse Models

T Cells from CLL Patients on Venetoclax Mount Potent Cytotoxic Responses in Combination with Epcoritamab, a CD20/CD3 Bispecific Antibody

T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia

Transcriptional Changes in Patients with CLL Starting Venetoclax Therapy Identifies Inflammatory and Adaptive Stress Responses

Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study

Extended Follow-up and Resistance Mutations in CLL Patients Treated with Acalabrutinib

A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies

NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts

NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies

Comprehensive Cardiac Testing in Asymptomatic Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib

Booster and Btki Interruption Improve Response to Sars-Cov-2 Vaccine in Patients with CLL

CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression Free Survival on BTK Inhibitor Therapy

Ibrutinib-Associated Sudden Death in Patients with CLL

Co-Stimulatory Signaling Boosts CAR T Cell Efficacy Against CLL

Longitudinal Mutation Profiling in CLL Patients during Acalabrutinib Therapy and at Progression

BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL

Humoral and Cellular Immunogenicity of COVID-19 Vaccinations in Patients with CLL

Effect of Bruton Tyrosine Kinase Inhibitor on Serologic and Cellular Immune Responses to Recombinant Zoster Vaccine

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only